Montelukast for Acute Bronchiolitis and Postbronchiolitis Viral Induced Wheezing
NCT ID: NCT01370187
Last Updated: 2011-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
146 participants
INTERVENTIONAL
2010-07-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children
NCT02541760
The Effect of Montelukast Treatment in Wheezy Infants
NCT00934713
Montelukast for Early Life Wheezing
NCT00115297
Evaluation of the Effectiveness of Montelukast in Children With Recurrent Obstructive Bronchitis
NCT04613180
Montelukast in Children With Wheezing
NCT00775697
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Control group
No interventions assigned to this group
Montelukast
4mg Montelukast daily for 2 months
Montelukast
Montelukast 4mg daily for 2 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Montelukast
Montelukast 4mg daily for 2 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* written informed consent by parents
Exclusion Criteria
* recent bronchodilator use
* immune deficient
* immunosuppressive drug use
* croup or pneumonia diagnosis
* loss of follow up
3 Months
12 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hormozgan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hormozgan University of Medical Sciences (HUMS)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ali Asghar Parhiz, Resident
Role: PRINCIPAL_INVESTIGATOR
Hormzgan University of Medical Sciences (HUMS)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hormozgan University of Medical Sciences (HUMS)
Bandar Abbas, Hormozgan, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Montelukast for bronchiolitis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.